A phase II trial of gemcitabine (G), carboplatin (C), and sorafenib (S) in patients (pts) with transitional cell carcinoma (TCC): Preliminary safety and outcome. Background: Frail and elderly patients ...
Prostate cancer researchers Urine cytology after an initial TURBT predicted risk for a second TURBT one month later. The following article features coverage from the American Urological Association ...
A trial tested an enhanced recovery after surgery (ERAS) protocol in patients who underwent ambulatory transurethral resection (TURBT) of bladder cancer.
PRINCETON, N.J--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
Bladder cancer is the seventh most common cancer in men, with nearly 400,000 cases diagnosed per year. However, despite the use of transurethral resection of the bladder tumor (TURBT), a large number ...
In patients with suspected muscle-invasive bladder cancer (MIBC), definitive treatment can be expedited by adding multi-parametric magnetic resonance imaging (mpMRI) to flexible cystoscopic biopsy at ...
MAIN-CAV: Phase III randomized trial of maintenance cabozantinib (CABO) and avelumab (Av) vs Av after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; ...
Treatment with UGN-102 in patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer demonstrated beneficial responses. Patients with recurrent low-grade intermediate-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results